The higher doses of mPD1-Fc-OX40L, which remain below the total dose of antibody administered, improved the rate of complete primary tumor rejection and were nearly 2–3 fold higher than was observed with two distinct combinations of PD1/L1 and OX40 antibodies. This evidence concerns the gene TNFSF4 and neoplasm.